AP NEWS

Skin & Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Insight, 2018 - ResearchAndMarkets.com

December 14, 2018

DUBLIN--(BUSINESS WIRE)--Dec 14, 2018--The “Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Skin & Skin Structure Infections (SSSI) Caused by Bacteria development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

The report provides a snapshot of the pipeline development The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration and molecule type The report also covers dormant and discontinued pipeline projects

Topics Covered

1. Report Introduction

2. Skin & Skin Structure Infections (SSSI) Caused by Bacteria Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Featured

GlaxoSmithKline Melinta Therapeutics Paratek Pharmaceuticals Debiopharm International MerLion Pharmaceuticals Nabriva Therapeutics Cempra Cellceutix Corporation Tetraphase Pharmaceuticals Durata Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/74kv73/skin_and_skin?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181214005313/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Dermatological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/14/2018 10:48 AM/DISC: 12/14/2018 10:47 AM

http://www.businesswire.com/news/home/20181214005313/en

AP RADIO
Update hourly